A Phase I, Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose Escalation Clinical Trial With Open-labelled Food Effect Study of Single Dose to Investigate the Safety, Tolerability and Pharmacokinetics of DA-6886 After Oral Administration in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2017
At a glance
- Drugs DA 6886 (Primary)
- Indications Irritable bowel syndrome
- Focus Adverse reactions
- Sponsors Dong-A ST
- 19 May 2015 Status changed from recruiting to completed, as reported at the Digestive Disease Week 2015.
- 12 Aug 2013 Planned End Date changed from 1 Aug 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 12 Jul 2012 New trial record